Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy of Pomalidomide and Dexamethasone in Patients with Multiple Myeloma and Relapsed and Refractory Light Chain (Al) Amyloidosis

Next Previous
X
Search
Trial Profile

Efficacy of Pomalidomide and Dexamethasone in Patients with Multiple Myeloma and Relapsed and Refractory Light Chain (Al) Amyloidosis

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Feb 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexamethasone (Primary) ; Pomalidomide (Primary)
  • Indications Amyloid light-chain amyloidosis; Multiple myeloma
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use

    • Most Recent Events

    • 04 Dec 2018 Status changed from recruiting to completed, as reported in an abstract presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
    • 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
    • 21 Jul 2017 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top